NeonMind Appoints Trevor Millar as Chief Psychedelic Officer
January 7, 2021
Ryan Allway January 7th, 2021 Psychedelics, Top News Vancouver, British Columbia–(Newsfile Corp. – January 7, 2021) – NeonMind Biosciences Inc. (CSE: NEON) (“NeonMind“), a company conducting research into the potentially therapeutic uses of compounds found in psychedelic mushrooms and commercializing medicinal mushroom products, is pleased to announce that it has appointed... Read more
NeonMind Commences Trading Under CSE Ticker Symbol “NEON”
January 4, 2021
Ryan Allway January 4th, 2021 Psychedelics, Top News NeonMind completed its oversubscribed Initial Public Offering on December 30, 2020, for gross proceeds of $4,600,000. NeonMind is a psychedelic drug development company. It’s mission is to help people change their lives by changing their minds, through treatment with psychedelics. NeonMind’s... Read more
Neonmind To Start Trading On CSE Today
January 4, 2021
Ryan Allway January 4th, 2021 Psychedelics Neonmind Biosciences Inc.’s common shares today commenced trading on the Canadian Securities Exchange under the ticker symbol NEON. More information on NeonMind can be found at www.neonmindbiosciences.com. NeonMind Commences Trading Under CSE Ticker Symbol “NEON”To view an enhanced version of this image, please... Read more
Ryan Allway January 4th, 2021 Psychedelics Empower Clinics (CSE:CBDT)(OTC PINK:EPWCF)(FRA:8EC) (“Empower”), an integrated healthcare company serving patients through clinics, a telemedicine platform, and a leading medical diagnostics laboratory processing thousands of COVID-19 specimens and developing novel COVID-19 testing protocols for CE, FDA EUA and Health Canada approval, is pleased... Read more
BetterPlant Subsidiary NeonMind Closes Oversubscribed Initial Public Offering and Exercise in Full of the Agent’s Over-Allotment Option
December 31, 2020
Ryan Allway December 31st, 2020 Psychedelics Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) is pleased to announce that its partially owned subsidiary NeonMind Biosciences Inc. (“NeonMind”) has successfully completed the maximum offering for its initial public offering (the “IPO”) of 46,000,000 units of NeonMind... Read more
Ryan Allway December 31st, 2020 Psychedelics BetterLife Pharma Inc. (“BetterLife” or the “Company”) CSE: BETR / OTCQB: BETRF / FRA: NPAU) an emerging biotech company, is pleased to announce that Patrick Kroupa and Justin Kirkland, two industry leaders in psychedelic therapeutics, have joined the Company. Mr. Kroupa and Mr.... Read more
Beckley Psytech announces £14m raise to conduct clinical trials on psychedelic medicine pipeline
December 30, 2020
Ryan Allway December 30th, 2020 Psychedelics Beckley Psytech, a psychedelic medicine company with deep ties to the historical Beckley Foundation, has raised £14m of new equity funding to develop psychedelic drugs into licensed pharmaceutical medicines for treating psychiatric and neurological diseases. New investors including Noetic Psychedelic Fund LP, a... Read more
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any... Read more
Allied Moves to Become Leader in Psilocybin Space with Intent to Acquire Pacific Sun Fungi
December 28, 2020
Ryan Allway December 28th, 2020 Psychedelics Allied Corp . (“Allied”) ( OTCQB: ALID ) – an international medical cannabis company focused on creating and providing health solutions to address today’s medical mental health issues is pleased to announce the signing of a letter of intent to acquire the psilocybin... Read more
Ryan Allway December 28th, 2020 Psychedelics Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has entered into a non-binding letter of... Read more
